BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
about
Developing and evaluating polygenic risk prediction models for stratified disease prevention.Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.Breast cancer risks and risk prediction models.Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effectsPost-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling.Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients.Gene-panel sequencing and the prediction of breast-cancer risk.iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management.Counsellee's experience of cancer genetic counselling with pedigrees that automatically incorporate genealogical and cancer database information.Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families.Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies.Non-invasive optical spectroscopic monitoring of breast development during puberty.Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scoresCombined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.The evolution of cancer surgery and future perspectives.Molecular epidemiology, and possible real-world applications in breast cancer.Classification and Clinical Management of Variants of Uncertain Significance in High Penetrance Cancer Predisposition Genes.Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries.Performance of BRCA1/2 mutation prediction models in male breast cancer patients.Family History of Breast Cancer, Breast Density, and Breast Cancer Risk in a U.S. Breast Cancer Screening Population.Testing for Gene-Environment Interactions Using a Prospective Family Cohort Design: Body Mass Index in Early and Later Adulthood and Risk of Breast Cancer.Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.A GPS-Based Methodology to Analyze Environment-Health Associations at the Trip Level: Case-Crossover Analyses of Built Environments and Walking.Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks.Breast cancer screening (BCS) chart: a basic and preliminary model for making screening mammography more productive and efficient.Dependence of cancer risk from environmental exposures on underlying genetic susceptibility: an illustration with polycyclic aromatic hydrocarbons and breast cancer.Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.pedigreejs: a web-based graphical pedigree editor.Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia.The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.Genetic testing in women with breast cancer: implications for treatment.Prediction of breast cancer risk based on flow-variant analysis of circulating peripheral blood B cells.Patient-Centered Care in Breast Cancer Genetic Clinics.Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability.
P2860
Q30251440-930B1903-C900-454C-A200-64BC9EF87945Q34339960-055152C9-EE3E-4F16-8FDE-83A6766FBF18Q35155449-AF240643-2F6E-4774-9BDC-2F1531C5ACA6Q35399596-6692D33E-9BAB-4FE5-9C0F-05E6744446ABQ35736188-53D6BA3C-3904-4487-932C-0588276B5515Q35848518-35A7F656-2D7D-435A-AA3F-9735E2303237Q35886203-8CD62112-9475-4459-BEB0-E4F7BE6D31A1Q35901598-09737452-BE3D-4192-9A95-B99A21D56BD3Q36175072-DE851619-45BC-4CF9-8066-98917C38E199Q36678510-60B280C8-7CE9-42D3-8B05-047649391C59Q37124135-EEE72761-2CDD-487F-A0A3-19E45CDC7FABQ37131918-1F68A79A-CCC9-4C79-9C79-CA27E9B6A7B2Q37378034-92B8551E-943A-41CA-98B4-F18A2253C8AEQ37524981-8026FD58-D04A-4CE6-BC3B-9374EA7BBA83Q37628084-DF340A8C-5280-49C7-B3AF-42A5ABE62D2AQ37710182-D00B8533-492E-45AC-BAD4-B07D8ACE74F1Q37716586-2CA059FE-339D-4B9E-8C1E-0CD174CABE86Q38266722-02111643-156E-4219-9119-8FC7ACA7EC6DQ38415320-1A1B7305-D428-48A3-A687-5DD4C6E9E91BQ38700025-9E9A2171-273D-4EB3-9BEA-275DAE56A27BQ38721663-BA57C5AF-D2B0-4FA6-AB6D-B688DCCEFCDAQ38739022-6C8C8290-1FC9-42F6-984D-842F121668ABQ38769347-D434400F-3EDE-46E4-8097-A27E7E37458DQ38842051-F4EBE239-E6D1-45A9-9D53-ED5DDE78FE81Q39263736-3F398BEB-B632-4A18-9AA1-5499FC14AE1EQ39326953-C9144B8F-D3D8-4C10-AA51-144635192F1AQ39360191-1592B3CF-D65B-4B22-9CEA-BF01CFEFF4ADQ39437211-551587B3-EB22-49C1-A0F1-7DF7B74E296DQ39958494-37401DE2-C3BC-40DC-AA28-E70C15CEC4A6Q40094101-81EC4335-F30C-486E-A593-998D636C42FDQ40201038-47224159-4511-49E1-B3A0-B583C26F4A5BQ40270211-F670C4F8-E2A7-458C-94FF-B036F9F33F98Q40903518-C1534090-D0FB-4599-A428-1D6729A607C0Q42695202-96EB5728-9790-44F5-A5F6-39B53A8C0E2CQ47586106-A613E6C6-E206-43EF-AF2B-4F543265AED4Q47686082-03D6C84A-7624-4B4C-AF0D-69680BFF5037Q47884776-037446F5-58DE-4FF6-A6EB-82C20A4EAF36Q48115820-6ECFE800-1148-415B-A3C2-3F76A5B06D0DQ50033737-35E7D4B2-7A0C-4E94-8090-6BAF24E67930Q51016187-9803EDC5-1721-4482-9B94-1F340A9DAE8F
P2860
BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
BOADICEA breast cancer risk pr ...... r pathology and web interface.
@en
BOADICEA breast cancer risk pr ...... r pathology and web interface.
@nl
type
label
BOADICEA breast cancer risk pr ...... r pathology and web interface.
@en
BOADICEA breast cancer risk pr ...... r pathology and web interface.
@nl
prefLabel
BOADICEA breast cancer risk pr ...... r pathology and web interface.
@en
BOADICEA breast cancer risk pr ...... r pathology and web interface.
@nl
P2093
P2860
P356
P1476
BOADICEA breast cancer risk pr ...... r pathology and web interface.
@en
P2093
A P Cunningham
Breast Cancer Association Consortium
Consortium of Investigators of Modifiers of BRCA1/2
K B Kuchenbaecker
N Mavaddat
P2860
P2888
P304
P356
10.1038/BJC.2013.730
P407
P577
2013-12-17T00:00:00Z
P5875
P6179
1032030618